CTOs on the Move

TLC Biopharmaceuticals

www.tlcbio.com

 
TLC Biopharmaceuticals is a South San Francisco, CA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
  • Number of Employees: 25-100
  • Annual Revenue: $1-10 Million
  • www.tlcbio.com
  • 432 N Canal St
    South San Francisco, CA USA 94080
  • Phone: 650.872.8816

Executives

Name Title Contact Details

Similar Companies

Avail Scientific

Avail Scientific is working to facilitate a medical and social revolution of the current pharmacological therapies for addiction and the underlying causes by providing evidence-based diagnostic and data acquisition programs. These substances can be used as both treatment for addiction and as preventative therapy by addressing the health challenges underlying substance abuse. We are building a platform to both educate and equip healthcare professionals with the data to use these therapeutic tools efficiently. Our objective is to treat this medical condition and prove out rehabilitation and preventative therapy programs with our partners in healthcare communities, both local and globally. Avail Scientific is positioned to become a global leader in eliminating the needless suffering that surrounds addiction and mental health issues by providing effective data and patient monitoring to validate their efficacy.

Highmark Delaware

Highmark Delaware is a Wilmington, DE-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Conversant Biologics

Conversant Biologics is a Huntsville, AL-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Terumo Heart

Terumo Heart, Inc. is a Ann Arbor, MI-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Boundless Bio

Boundless Bio, a San Diego based company backed by ARCH Venture Partners, is discovering and developing novel cancer therapeutics based on the role of extrachromosomal DNA (ecDNA) in driving tumorigenesis, resistance and recurrence. When DNA in cancer cells comes off chromosomes, “extrachromosomal DNA (ecDNA),” it becomes unbound and unwound, thereby enabling numerous copies of cancer-causing genes, driving cancer cells to grow and allowing them to resist treatment. At Boundless Bio, we are counterattacking this ecDNA phenomenon with boundless innovation and boundless energy to develop powerful new cancer medicines that eliminate cancer cells’ ability to employ ecDNA to survive.